Plasma cell populations can be identified based on the expression of CD45, CD38, and the more plasma cell-specific marker CD138. These markers allow plasma cells to be classified as either normal ...

The immunophenotype of tumor cells includes strong ALK expression (ALK gene rearrangement) and expression of plasma-cell markers CD38, CD138, and VS38C. CD20a, Pax-5, CD79, and B-cell markers are ...

Background: Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and ...

11,30 Cells were incubated with 2 µg/ml PE together with the respective surface makers for detection of PE-specific CD38 memory B cells. Anti-PE antibody producing plasma cells were identified by ...

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...

Immunostaining for CD138 (Panel B) shows that plasma cells account for approximately 40% of the marrow cellularity. Hematoxylin and eosin staining of a section of the fat-pad biopsy specimen ...

CD38, an enzyme involved in neuroinflammation and cellular senescence, has recently been implicated in these processes. However, its specific role in CEC dysfunction within the context of VaD remains ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator ...

Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, Fujian 350117 ...